Plasma Ceramide test is now available at Mayo Clinic Medical Laboratories
Plasma Ceramides predict adverse cardiovascular events. Elevated plasma ceramide concentrations are risk factors for cardiovascular mortality, myocardial infarction and acute coronary syndrome hospitalizations. Plasma ceramides…
Read moreZora and Mayo Medical Laboratories to collaborate on Plasma Ceramide Testing
Zora and Mayo Medical Laboratories has signed Collaborate on Plasma Ceramides Testing. The test will be launched in summer, and is used to predict adverse…
Read moreZora at EAS 2016 Innsbruck
Zora participates 84th EAS Congress at Innsbruck, Austria. Our CMO Reijo Laaksonen presents our latest results on cardiovascular risk prediction in statin treated patients at…
Read moreZora at Nature Reviews Research Highlights
Zora's recent publication on CERT was reviewed in Nature Reviews Cardiology Research Highlights. Read the research highlight here.
Read moreNew biomarker for identification of coronary artery disease patients at high risk for cardiovascular death
Zora Biosciences in collaboration with academic research groups from Finland, Germany, Austria, Switzerland and Norway have shown that plasma ceramides are significant predictors of cardiovascular…
Read moreZora has updated visual identity
We have renewed our visual identity. Zora logo is now modernized. Inspiration for the new logo comes from the six carbon ring that is commonly…
Read more